A Study to Determine the Effect of Multiple Oral Doses of SLx-2119 in Healthy Male Subjects

Completed · Phase 1 · Has a placebo group

Conditions studied: Immune System Disorder (Healthy Volunteer)

In brief

The purpose of this study is to determine the safety, tolerability, and pharmacokinetics of multiple doses of SLx-2119 in healthy male participants.

Key facts

Study ID

NCT05918627

Run by

Kadmon, a Sanofi Company

People needed

32

Starts

2009-09-21

Expected to finish

2009-12-09

Last updated by the study team

2023-06-26

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Healthy participants between the ages of 18 and 55 years, inclusive.
• Able to provide written informed consent prior to the performance of any study specific procedures.
• Body mass index (BMI) range of 19-30 kilogram per square meter (kg/m2), inclusive.

You may not qualify if…

• Participants are excluded from the study if any of the following criteria apply:
• Past or present disease that is judged by the investigator to have the potential to interfere with the study procedures, compromise safety, or affect the PK evaluations.
• Known sensitivity to Rho-associated coiled-coil containing serine/threonine protein kinases (ROCK2) inhibitor agents or to any of the constituents of the KD025 formulation.
• The above information is not intended to contain all considerations relevant to the potential participation in a clinical trial.

Where it is running

• Investigational site — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.